| Description | Sonlicromanol hydrochloride (KH176 hydrochloride) is a ROS-redox modulator that crosses the blood-brain barrier, has potential anticancer activity, improves m.3243A>G heterogeneity in iPSC-derived neurons associated with It has potential anticancer activity, ameliorates neuronal network dysfunction and transcriptomic changes associated with m.3243A>G heterogeneity in iPSC-derived neurons, and can be used for the treatment of mitochondrial diseases. |
| In vivo | 在 Ndufs4−/− 小鼠（利维氏病模型）中，Sonlicromanol hydrochloride（10 mg/kg；腹腔注射，每日一次）显著改善了转筒和步态表现，减少了视网膜神经节细胞的退行性变。此外，导致外囊的FA值显著增加，并且在脑脚盆中显示出类似的趋势[1]。 |
| Synonyms | KH 176 hydrochloride |
| molecular weight | 368.9 |
| Molecular formula | C19H29ClN2O3 |
| CAS | 2162149-24-6 |
| Storage | store under nitrogen,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 150 mg/mL (406.61 mM), Sonification is recommended. H2O: 80 mg/mL (216.86 mM.) |
| References | 1. Ria de Haas, et al. Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease. Sci Rep. 2017 Sep 15;7(1):11733. |